|
What were your educational needs at the start of the activity? | |
Were your educational needs met? | |
Describe the pathophysiology of severe familial hypercholesterolemia including the role of apolipoprotein B and lipoprotein(a) in lipid homeostasis. | |
Implement diagnostic strategies in pediatric and adult patients to appropriately risk stratify patients for genetic lipid disorders. | |
Utilize current treatment recommendations for improving the outcomes of patients with severe FH to reduce their elevated risk of CHD. | |
Track patient outcomes data to improve clinical research and decision-making that will improve identification of patients at risk for FH. | |
If "Not Met", please explain for each objective.
|
Mary P. McGowan, MD | |
Daniel J. Rader, MD | |
James A. Underberg, MD | |
Did the speakers encourage questions/discussion or other participation from the audience?
| |
If the answer is no, please explain: | |
Was the content presented examined with sceintific rigor and evidence-based? | |
Was the scope, depth, and level of content appropriate? | |
Did the invitation and syllabus accurately convey the purpose and content? | |
Did the speaker provide a disclosure and disclose any off-label/investigational use of products discussed during their presentation? | |
Were the activities (e.g. speaker questions/discussion, case studies) that assessed learning appropriate? | |
Was the acitivity fair, balanced, and free of commercial bias? | |
If you answered 1, 2, or 3 in the above question, please describe the factors that contributed to the bias:
|
As a result of participating in this activity, what will you do differently to improve the care of your patients? (Note: You will be reminded of this answer in a follow-up email survey)
|
Implementation of Treatment Guidelines | |
Clinical Trial Updates | |
Genetic disorders and testing | |
Advanced lipid testing | |
Emerging biomarkers of atherosclerosis | |
Atherosclerosis Imaging | |
Hypertriglyceridemia | |
Metabolic syndrome, diabetes, insulin resistance | |
Hypertension | |
Obesity management and weight loss | |
Acute Coronary Syndrome | |
HDL-C therapies | |
Aggresive LDL-C lowering through combination therapies | |
Special Populations: Women, Pediatrics, Ethnic Groups, HIV | |
Other: | |
Additional comments or suggestions for improvement? | |
|